Canandaigua National Bank & Trust Co. continued to hold its position in GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,769 shares of the pharmaceutical company’s stock at the end of the second quarter. Canandaigua National Bank & Trust Co.’s holdings in GlaxoSmithKline PLC were worth $250,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Cribstone Capital Management LLC purchased a new position in GlaxoSmithKline PLC during the second quarter valued at about $117,000. Williams Jones & Associates LLC purchased a new position in GlaxoSmithKline PLC during the first quarter valued at about $161,000. LS Investment Advisors LLC raised its position in GlaxoSmithKline PLC by 167.5% in the second quarter. LS Investment Advisors LLC now owns 4,280 shares of the pharmaceutical company’s stock valued at $185,000 after buying an additional 2,680 shares during the last quarter. Cape Cod Five Cents Savings Bank purchased a new position in GlaxoSmithKline PLC during the second quarter valued at about $201,000. Finally, Forester Capital Management LTD raised its position in GlaxoSmithKline PLC by 69.6% in the first quarter. Forester Capital Management LTD now owns 4,630 shares of the pharmaceutical company’s stock valued at $214,000 after buying an additional 1,900 shares during the last quarter. 8.79% of the stock is currently owned by hedge funds and other institutional investors.

GlaxoSmithKline PLC (NYSE:GSK) traded up 0.86% during mid-day trading on Thursday, reaching $43.58. The company’s stock had a trading volume of 1,899,058 shares. GlaxoSmithKline PLC has a 52 week low of $37.24 and a 52 week high of $45.58. The stock has a market capitalization of $105.92 billion, a price-to-earnings ratio of 2723.75 and a beta of 0.85. The firm has a 50-day moving average of $43.80 and a 200-day moving average of $42.61.

The business also recently disclosed a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Friday, August 12th will be paid a dividend of $0.494 per share. The ex-dividend date of this dividend is Wednesday, August 10th. GlaxoSmithKline PLC’s dividend payout ratio is presently 6,600.00%.

Several equities analysts recently issued reports on the company. Citigroup Inc. reissued a “buy” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, June 23rd. Beaufort Securities restated a “buy” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, June 21st. HSBC restated a “buy” rating on shares of GlaxoSmithKline PLC in a report on Monday, September 12th. Cowen and Company downgraded GlaxoSmithKline PLC from an “outperform” rating to a “market perform” rating in a report on Thursday, May 26th. Finally, Shore Capital restated a “hold” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, June 21st. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $47.53.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.